Australia’s drug regulator, the Therapeutic Goods Administration (TGA), announced in October 2020 the approval of etanercept and insulin aspart biosimilars.
Australia approves etanercept and insulin aspart biosimilars
Biosimilars/News
|
Posted 04/12/2020
0
Post your comment
Etanercept is a is a human tumour necrosis factor receptor p75 fragment crystallizable fusion protein and is a drug used to treat inflammatory conditions. This latest biosimilar has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in adults. It has also been approved for the treatment of several juvenile arthritic conditions and juvenile plaque psoriasis.
On 23 October 2020, the TGA also announced the approval of the insulin aspart biosimilar Truvelog for the treatment of diabetes mellitus. Truvelog, which is made by Sanofi-Aventis, is a biosimilar of NovoRapid Penfill and NovoRapid FlexPen. This will be the first rival of the reference product to enter the Australian market.
Insulin aspart is a type of manufactured insulin that is administered by injection to control blood sugar levels in people with type 1 and type 2 diabetes. It acts more rapidly than normal human insulin (within 15 minutes) and its effects last for 3–5 hours.
Sanofi also received approval for its insulin aspart biosimilar in Europe in July 2020 [2].
Related articles
Switching from biologicals to biosimilars in Australia
Australia approves five biosimilars since June 2019
Australian guidelines for biosimilars
|
LATIN AMERICAN FORUM We are pleased to announce, that starting January 2021, the launch of a new section on GaBI Online, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America. Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. |
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Australia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Dec 4]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Australia
1. GaBI Online - Generics and Biosimilars Initiative. EC approval for Sanofi’s insulin aspart biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Dec 4]. Available from: www.gabionline.net/Biosimilars/News/EC-approval-for-Sanofi-s-insulin-aspart-biosimilar
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.
Source: TGA
Research
Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
Biosimilars in inflammatory bowel disease: are we ready for multiple switches
General
Humira's resilience in the face of biosimilar competition
Boehringer Ingelheim to expand access to adalimumab biosimilar
Related content
Richmond to launch similar biologicals bevacizumab Yriviak and adalimumab Armixa
Biosimilars/News Posted 06/08/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment